For the Inventor, By the Inventor

Enter assignee name

Cranford, NJ, United States of America

Enzon Pharmaceuticals, Inc.

USPTO Granted Patents = 52

EPO Patents = 5

Trademarks = 1

Forward Citations = 765

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Hong Zhao (25 out of 36 patents)

Richard B Greenwald (11 out of 61 patents)

Charlotte Albaek Thrue (8 out of 19 patents)

4. Majken Westergaard (7 out of 17 patents)

5. Puja Sapra (6 out of 7 patents)

6. Dechun Wu (5 out of 8 patents)

7. Jesper Worm (5 out of 10 patents)

8. Paul E G Kristjansen (4 out of 6 patents)

9. Maria Belen Rubio (4 out of 4 patents)

10. Margit Wissenbach (4 out of 4 patents)

11. Belen Rubio (4 out of 4 patents)

12. Frank Winther Rasmussen (3 out of 53 patents)

13. Henrik Frydenlund Hansen (3 out of 32 patents)

14. Anja Molhart Hog (3 out of 4 patents)

15. Susan L Adler, Legal Representative (3 out of 3 patents)

Core Competencies:

LNA Antisense Oligonucleotides

Polymeric Prodrugs

Biodegradable Linkers

Multi-arm Polymeric Conjugates

RNA Antagonists

HIF-1A Modulation

Androgen Receptor Targeting

Beta-Catenin Expression

Survivin Modulation

Oligomeric Compounds

Nucleic Acid Delivery

Cancer Treatment

52 patents: Sort by Forward Citations

1. 9506060 - LNA antisense oligonucleotides for the modulation of Myc expression (2016-11-29),

2. 8450290 - Methods for treating androgen receptor dependent disorders including cancers (2013-05-28),

3. 8410071 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2013-04-02),

4. 8367065 - Targeted polymeric prodrugs containing multifunctional linkers (2013-02-05),

5. 8357670 - Oligomeric compounds for the modulation of HIF-1A expression (2013-01-22),

6. 8299089 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers (2012-10-30),

7. 8268793 - RNA antagonist compounds for the modulation of HER3 (2012-09-18),

8. 8268318 - Polyalkylene oxides having hindered ester-based biodegradable linkers (2012-09-18),

9. 8207140 - Oligomeric compounds for the modulation of HIF-1α expression (2012-06-26),

10. 8192743 - Releasable polymeric conjugates based on aliphatic biodegradable linkers (2012-06-05),

11. 8173428 - LNA oligonucleotides and the treatment of cancer (2012-05-08),

12. 8168605 - Polymeric oligonucleotide prodrugs (2012-05-01),

13. 8133707 - Methods of preparing activated polymers having alpha nitrogen groups (2012-03-13),

14. 8110559 - Hindered ester-based biodegradable linkers for oligonucleotide delivery (2012-02-07),

15. 8048891 - Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin (2011-11-01),

Enzon Pharmaceuticals, Inc., is a biopharmaceutical company engaged in the research and development of therapeutics for patients with high unmet medical needs. Enzon's focus is on delivering innovative antibody-drug conjugate (ADC) and RNA-based therapeutics to improve treatment outcomes and quality of life. With a commitment to scientific excellence and a dedication to patients, Enzon aims to make a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#1 in Cranford, NJ

#275 in New Jersey

#6,544 in US

#13,161 in the World

Cranford, NJ, United States of America

Enzon Pharmaceuticals, Inc.

Forward Citations = 765

43 inventors:

Hong Zhao (25 out of 36 patents)

Richard B Greenwald (11 out of 61 patents)

Charlotte Albaek Thrue (8 out of 19 patents)

4. Majken Westergaard (7 out of 17 patents)

5. Puja Sapra (6 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…